Itraconazole: Difference between revisions
From IDWiki
No edit summary |
(added adverse effects) |
||
| Line 6: | Line 6: | ||
* Target in prophylaxis is a trough ot 0.5 mg/L |
* Target in prophylaxis is a trough ot 0.5 mg/L |
||
* Target in treatment is a trough >0.5 mg/L |
* Target in treatment is a trough >0.5 mg/L |
||
| + | |||
| + | == Adverse Effects == |
||
| + | * Headaches |
||
| + | * Relative adrenal insufficiency |
||
| + | * Hepatotoxicity |
||
| + | * QTc prolongation |
||
[[Category:Antifungals]] |
[[Category:Antifungals]] |
||
Revision as of 11:04, 21 November 2019
- Azole antifungal
- Indications include Alternaria, Blastomyces dermatitidis, Chromoblastomycosis, Coccidioides immitis, Cryptococcus, Entomophthoromycotina, Exophiala, Exserohilum, Fonsecaea, Histoplasma capsulatum, Mycetoma, Paracoccidioides brasiliensis, Sappinia diploidea, Sporothrix schenckii
Therapeutic Drug Monitoring
- Should be measured 5 to 7 days after starting or changing the dose, or when interacting medications are changed
- Target in prophylaxis is a trough ot 0.5 mg/L
- Target in treatment is a trough >0.5 mg/L
Adverse Effects
- Headaches
- Relative adrenal insufficiency
- Hepatotoxicity
- QTc prolongation
